Effects of dexmedetomidine combined with sufentanil on injury and expression of high mobility group box protein B1/toll-like receptors signaling pathway in rats with pancreatitis

Abstract

Pancreatitis is a common disease of digestive system, easy to deteriorate, acute onset, poor prognosis, high fatality rate. Analgesic and sedative drugs are often used to treat pancreatitis. Dexmedetomidine is an adrenergic receptor agonist, and Sufentanil is a common analgesic sedative. However, the mechanism of their combined use in the treatment of pancreatitis injury has not been fully elucidated. Wistar rat pancreatitis Model was established and randomly divided into 4 groups: Dex group, Dex+Suf group, model group and Sufentanil group. Compare and analyze heart rate, oxygen saturation, body temperature, and respiration. The onset time, duration, analgesic time and adverse reactions were recorded. Serum amylase, creatinine and alanine aminotransferase were detected. Serum IL-6 and IL-1β levels were detected, and apoptotic activity was detected by Caspase 3 activity kit. The expression of HMGB1, TLR2 and TLR4 mRNA in pancreatic tissues. Dexmedetomide alone or combined with sufentanil can improve the general indicators, sedation and analgesia time is shorter, longer duration. Serum secretion of IL-6 and IL-1β decreased, expression of HMGB1, TLR2 and TLR4 decreased, pancreatic serological serum amylase, creatinine, alanine aminotransferase activities decreased, Caspase 3 activity decreased. The curative effect of combination group was significantly higher than that of model group (p < 0.01). Dexmedetomidine combined with sufentanil can affect the expression of HMGB1/TLRs, inhibit inflammation, improve sedation and analgesia, and inhibit apoptosis, so as to alleviate the injury of acute pancreatitis.